| Website | lillyventures.com |
| Phone | 3176513050 |
| Employees | 4 |
| Description | Pharmaceutical Investor |
| First Fund, 8/09 | $200M |
Lilly Ventures is the venture capital arm of Eli Lilly and Company responsible for life science investing in North America and Europe. Our primary goal is to facilitate the success of companies in our areas of focus through early to expansion stage investments and value-adding resources.
Lilly Ventures currently has $200 million under management and focuses on three major areas of interest.
| Company | Date | Round | Size | Participants |
| Cerulean Pharma | 12/11 | Series D | $15M | 5 |
| Nimbus Discovery | 6/11 | Series A | $24M | 3 |
| Sutro Biopharma | 11/10 | Series C | $36.5M | 5 |
| Cerulean Pharma | 11/10 | Series C | $24M | 5 |
| Cylene Pharmaceuticals | 9/10 | Series D | $12M | 6 |
| HemaQuest | 4/10 | Series B | $12M | 4 |
| FORMA Therapeutics | 12/09 | Series B | $3M | 3 |
| FORMA Therapeutics | 12/09 | Series B | $25.5M | 3 |
| Receptos | 11/09 | Series A | $25M | 4 |
| Trinity Biosystems | 11/09 | Unattributed | $7.5M | 5 |
| Viamet Pharmaceuticals | 7/09 | Series B | $18M | 6 |
| Aileron Therapeutic | 6/09 | Series D | $40M | 6 |
| Avid Radiopharmaceuticals | 5/09 | Series D | $34.5M | 7 |
| Intradigm Corporation | 1/09 | Series B | $21.4M | 8 |
| Avid Radiopharmaceuticals | 5/07 | Series C | $26M | 6 |
| Cylene Pharmaceuticals | 1/07 | Series C | $44M | 2 |
| Fluidigm | 1/07 | Series E | $17M | 10 |
| Protagonist | 9/06 | Series A | $9M | 3 |
| MedManage Systems | 4/06 | Series D | $10.8M | 4 |
| InnoCentive | 2/06 | Series A | $9M | 3 |
| Avid Radiopharmaceuticals | 1/06 | Series A | $8.9M | 4 |
